p16 INK4a is a tumor suppressor protein involved in the pathogenesis of a variety of malignancies and is a 16.5 kDa protein expressed in the nucleoplasm of proliferating cells, functioning as an inhibitor of CDK4. Recent analyses of the p16INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. p16 INK4a […]
February 13, 2020 – Biocare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, announces the launch of seven novel IVD IHC antibody markers for clinical diagnostics and research applications.The most recent launch focuses on several immuno-oncology markers, critical in aiding early-stage cancer drug developments and patient treatment. Biocare re-developed a major […]
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a member of the CD28 superfamily and is a negative regulator of T cell-mediated immune responses. CTLA-4 expression is induced on the surface of T cells after CD28 binding and activation, and is constitutively expressed on T-regulatory cells, acting as an immune checkpoint inhibitor, downregulating T cell activity. (1-3). […]
LAG-3 (Lymphocyte Activation Gene 3) is a surface receptor expressed on activated T cells, an exhaustion marker with immunosuppressive activity (1). Major histocompatibility complex class II (MHC-II) is a ligand for LAG-3; additional ligands (e.g., LSECtin and galectin-3) have also been identified (1,2). Regulatory T cells (Tregs) expressing LAG-3 have enhanced suppressive activity, whereas cytotoxic […]
Biocare Medical takes great pride in our promise of “Fighting Cancer, One Slide at a Time.” Our focus in the fight against cancer is realized through our high-quality immunohistochemistry (IHC) and in situ hybridization (ISH) reagents and instrumentation. Specifically, our sensitive and specific antibodies, molecular probes, and detection chemistries support early and accurate classification of […]
Early on, Biocare recognized the market need for evaluating morphologically distinct markers to aid in solving complex clinical problems and simplifying interpretation, all while conserving precious patient tissue. The most glaring clinical need was determined to be the ability to differentiate between prostatic intraepithelial neoplasia (PIN) and carcinoma of the prostate. There also needed to […]
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a member of the CD28 superfamily and is a negative regulator of T cell-mediated immune responses. CTLA-4 exhibits cell surface and intracellular constitutive expression on memory T-cells and at a low level by T-regulatory cells (Tregs; 2-4% of circulating CD4+ T cells) (1,2). CTLA-4 primarily inactivates T-cell activity by […]
MART-1 recognizes a protein of 18 kDa, identified at MART-1 (Melanoma Antigen Recognized by T cells 1). MART-1 is a useful addition to melanoma panels as it is specific for melanocytic lesions (1- 3). Studies have shown that MART-1 is more sensitive than HMB45 when labeling metastatic melanomas (3). Tyrosinase is a key enzyme involved […]
CD137, a member of the tumor necrosis factor receptor superfamily, represents a promising target for enhancing antitumor immune responses (1). The functions of CD137 in T lymphocytes include regulating activation, proliferation and apoptosis (2). CD137 helps regulate the activation of many immune cells, including CD4(+) T cells, CD8(+) T cells, dendritic cells, and natural killer […]
FOXP3 [86D] is a mouse monoclonal antibody that is intended for laboratory use in the qualitative identification of FOXP3 protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of […]
